Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 33, 2024 - Issue 1
Submit an article Journal homepage
1,380
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Potential of muvalaplin as a lipoprotein(a) inhibitor

Amanda J. Hoopera Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia;b School of Medicine, University of Western Australia, Perth, Western Australia, AustraliaView further author information
,
P. Mihika S. Fernandoa Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, AustraliaView further author information
&
John R. Burnetta Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia;b School of Medicine, University of Western Australia, Perth, Western Australia, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0135-6119View further author information
ORCID Icon
Pages 5-7 | Received 02 Nov 2023, Accepted 03 Jan 2024, Published online: 08 Jan 2024

References

  • Berg K. A new serum type system in man—the Lp System. Acta Pathol Microbiol Scand. 1963;59(3):369–382. doi: 10.1111/j.1699-0463.1963.tb01808.x
  • McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12-18;330(6144):132–137. doi: 10.1038/330132a0
  • Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925–3946. doi: 10.1093/eurheartj/ehac361
  • Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48–e60.
  • Chemello K, Chan DC, Lambert G, et al. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis. 2022 May;349:82–91.
  • Marcovina SM. Lipoprotein(a): a genetically determined risk factor for cardiovascular disease. Crit Rev Clin Lab Sci. 2023 Jul;14:1–13.
  • Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nat Rev Cardiol. 2023 Oct 17. doi: 10.1038/s41569-023-00937-4
  • de Boer LM, Oorthuys AOJ, Wiegman A, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 May 5;29(5):779–792. doi: 10.1093/eurjpc/zwab171
  • Schettler VJJ, Peter C, Zimmermann T, et al. The German Lipoprotein Apheresis Registry-Summary of the ninth annual report. Ther Apher Dial. 2022 Dec;26(Suppl 1):81–88.
  • Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower lipoprotein(a). Atherosclerosis. 2022 May;349:110–122. doi: 10.1016/j.atherosclerosis.2022.04.020
  • Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020 Jan 16;382(3):244–255. doi: 10.1056/NEJMoa1905239
  • O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022 Nov 17;387(20):1855–1864. doi: 10.1056/NEJMoa2211023
  • Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022 May 3;327(17):1679–1687. doi: 10.1001/jama.2022.5050
  • Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023 Sep 19;330(11):1042–1053.
  • Malick WA, Goonewardena SN, Koenig W, et al. Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2/3. J Am Coll Cardiol. 2023 Apr 25;81(16):1633–1645. doi: 10.1016/j.jacc.2023.02.033

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.